FDA adds enterocolitis risk warning to approved CAR-T cell therapy
The US Food and Drug Administration (FDA) approved updates to the prescribing information for ciltacabtagene autoleucel (CARVYKTI). The agency added a boxed warning
Multiple Myeloma
News
Cellular Therapy
Lymphoma
Mantle Cell Lymphoma
Liso-cel receives expanded approval in R/R MCL by European Commission
The European Commission expanded approval of the CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (liso-cel; Breyanzi®) in patients with relapsed or refractory
Multiple Myeloma
Video Interviews
Dr. Abdallah on blenrep combo approval in relapsed myeloma
In this video interview with SOHO Insider Al-Ola A. Abdallah, MD, associate professor and director of the Plasma Cell Disorder program at the
Lymphoma
Indolent B-Cell Lymphomas
News
FDA approves epcoritamab combo in R/R follicular lymphoma
The US Food and Drug Administration (FDA) approved epcoritamab (EPKINLY) in combination with rituximab, lenalidomide, and lenalidomide (RLL) for adult patients with relapsed
Ambassador Program
News
Society Updates
SOHO Egypt 2025 debuts with 2-day meeting in Cairo
The inaugural SOHO-EGYPT Meeting (November 5 to 6) was a joint session within NCI's BGO 2025 Congress ("Bridging Gaps in Oncology," November 5
Multiple Myeloma
News
Society Updates
Young Investigator Program
SOHO Young Investigator spotlight: Meet Maha Hameed, MD
As a resident physician who is fascinated by hematologic malignancies, Maha Hameed, MD, brings a distinctive combination of scientific intrigue and personal drive
Ambassador Program
News
Society Updates
SOHO KSA holds 3rd successful regional meeting
SOHO KSA held its first regional meeting in Riyadh, the Kingdom of Saudi Arabia (KSA). The two-day event was held at the Intercontinental
Multiple Myeloma
DARZALEX FASPRO® gets FDA approval to treat HR-smoldering multiple myeloma
The US Food and Drug Administration has approved daratumumab co-formulated with hyaluronidase (DARZALEX FASPRO®), as a single-agent therapy for adults with high-risk smoldering multiple
Multiple Myeloma
News
US FDA grants interchangeable designation for denosumab-bnht
The US Food and Drug Administration (FDA) granted interchangeable biosimilar designation to denosumab-bnht (Bomyntra) for patients with multiple myeloma (MM) to prevent skeletal-related
SOHO 2025
Leukemia
Chronic Lymphocytic Leukemia
Meetings / Conferences
News
SOHO pilot program finds structured learning improves practice in R/R CLL/SLL
At the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), a new pilot program debuted to educate and empower the